A 14% rip off the $7.12 open to $8.12 adds roughly a seventh to a $3.4 billion market cap in one session. Moves this size rarely settle quietly, so keep an eye on whether the gain holds into the next open.
A 14% rip off the $7.12 open to $8.12 adds roughly a seventh to a $3.4 billion market cap in one session. Moves this size rarely settle quietly, so keep an eye on whether the gain holds into the next open.
Jim Cramer says bears have a specific target in their crosshairs, and it runs deeper than one company’s IPO. The S-1 gives both sides real ammunition, and the number that will settle the argument has not been disclosed yet.
Chip stocks rallied, per CNBC, as the S&P 500 snapped a three-day skid on Election Day.
Opendoor marked a new 52-week low at $1.74, taking out yesterday's floor by another 3.3% and leaving the iBuyer worth $1.7 billion. A year ago the stock traded above $7.
Edwards Lifesciences cleared its July 6 ceiling by a hair at $95.20, a fresh 52-week high for the $54.8 billion heart valve maker. The stock has climbed back from $78 in February without a new peak until now.
A 4.96% slide to $530.76 is a rare one-day drawdown for a $134.5 billion biotech that usually trades with far less drama. Watch whether the after-hours level holds into tomorrow's open.
Sponsored
A $900,000 traditional 401(k) sitting untouched looks like a blessing until the IRS steps in at 75 and forces a withdrawal that does far more damage to a retiree’s tax bill than the dollar amount alone suggests.
Three Vanguard sector funds drew from completely different economic engines over the past year, with one surging over 50% while another barely budged, yet the laggard paid the fattest yield. Here is what a million-dollar split across utilities, energy, and financials actually pr…
The 26% earnings miss is almost entirely below the line, driven by non-operating charges including deferred tax from peso depreciation. Underneath, adjusted EBITDA rose 10% sequentially and management guided fourth-quarter EBITDA broadly flat, with a $0.90 per ADS interim dividend paying November 17.
So it's really just Intel that's incompetent
A 45% revenue jump and near-doubled data center sales just answered the AI-overspending selloff that hit the stock days earlier. The thread's real lesson is in the trader who sold minutes before close: timing an earnings move is how gains get donated.
Adjusted EPS beat expectations by 37% on Connected Living mobile device protection volumes, and management raised the full-year outlook to roughly 10% adjusted EBITDA growth excluding catastrophes. Buybacks for 2026 are now set at $350 million.
Shares slipped after hours despite a double beat and a raised full-year sales floor, because management flagged softer fourth-quarter profitability as costs and reinvestment hit Health & Biosciences. A $236 million held-for-sale loss on the Botanicals disposal group pushed GAAP continuing operations to a per-share loss, even as Scent carried the quarter.